Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:CTXROTCMKTS:GPLBOTCMKTS:INBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.11-10.0%$7.85$6.51▼$13.27$8.60M1.6294,006 shs5,240 shsCTXRCitius Pharmaceuticals$0.92-8.9%$0.85$0.65▼$26.25$9.04M0.87635,209 shs1.02 million shsGPLBGreen Planet Bioengineering$0.11$0.11$0.00▼$0.70$2.20M3.07955 shsN/AINBPIntegrated BioPharma$0.29-7.0%$0.30$0.16▼$0.42$8.93M0.7521,821 shs24,000 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+1.98%+8.24%+12.48%+24.50%-1.24%CTXRCitius Pharmaceuticals-4.72%+15.56%+29.39%-34.84%-93.71%GPLBGreen Planet Bioengineering0.00%0.00%0.00%-78.43%+21,900.00%INBPIntegrated BioPharma0.00%+10.32%+21.00%+1.01%+29.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.5243 of 5 stars3.55.00.00.02.00.80.0CTXRCitius Pharmaceuticals2.4306 of 5 stars3.42.00.00.02.50.81.3GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AN/AN/AINBPIntegrated BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00269.91% UpsideCTXRCitius Pharmaceuticals 2.80Moderate Buy$54.505,823.91% UpsideGPLBGreen Planet Bioengineering 0.00N/AN/AN/AINBPIntegrated BioPharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GPLB, INBP, CTXR, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K21.27N/AN/A$1.20 per share6.76CTXRCitius PharmaceuticalsN/AN/AN/AN/A$8.02 per shareN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AINBPIntegrated BioPharma$50.32M0.18$0.04 per share7.35$0.65 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%N/ACTXRCitius Pharmaceuticals-$39.14MN/A0.000.74N/AN/A-51.69%-37.60%8/11/2025 (Estimated)GPLBGreen Planet BioengineeringN/AN/A0.00∞N/AN/AN/AN/AN/AINBPIntegrated BioPharma$110K$0.049.61∞N/A1.78%4.79%3.54%N/ALatest GPLB, INBP, CTXR, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/14/2025Q3 2025INBPIntegrated BioPharmaN/A$0.02N/A$0.02N/A$13.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AINBPIntegrated BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59CTXRCitius PharmaceuticalsN/A0.410.17GPLBGreen Planet BioengineeringN/AN/AN/AINBPIntegrated BioPharmaN/A3.261.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%CTXRCitius Pharmaceuticals16.88%GPLBGreen Planet BioengineeringN/AINBPIntegrated BioPharma25.25%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%CTXRCitius Pharmaceuticals10.70%GPLBGreen Planet BioengineeringN/AINBPIntegrated BioPharma67.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableCTXRCitius Pharmaceuticals209.83 million7.55 millionOptionableGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionableINBPIntegrated BioPharma15030.98 million9.94 millionNot OptionableGPLB, INBP, CTXR, and ADXN HeadlinesRecent News About These CompaniesEliem Therapeutics (NASDAQ:ELYM) and Integrated BioPharma (OTCMKTS:INBP) Critical ReviewJune 3, 2025 | americanbankingnews.comIntegrated BioPharma Reports Results for its Quarter Ended March 31, 2025May 14, 2025 | accessnewswire.comIntegrated BioPharma Secures New Credit Line with PNCApril 21, 2025 | tipranks.comIntegrated BioPharma Reports Results for its Quarter Ended December 31, 2024February 13, 2025 | accessnewswire.comIntegrated BioPharma Reports Results for its Quarter Ended September 30, 2024November 13, 2024 | accesswire.comIntegrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024September 20, 2024 | accesswire.comAbbott partners with maker of ‘bionic pancreas’September 5, 2024 | medtechdive.comIntegrated Biopharma Inc (INBP)September 1, 2024 | investing.comShanghai unveils US$13.7 billion capital injection into IC, AI, and biopharma industriesAugust 1, 2024 | digitimes.comIntegrated BioPharma, Inc. (INBP)July 19, 2024 | finance.yahoo.comIntegrated BioPharma Reports Results for its Quarter Ended March 31, 2024May 10, 2024 | accesswire.comIntegrated nanoelectronics for the futureFebruary 19, 2024 | nature.comIntegrated BioPharma Reports Results for its Quarter Ended December 31, 2023February 12, 2024 | finance.yahoo.comHow to buy the best integrated washing machineFebruary 2, 2024 | which.co.ukKBI Biopharma and Argonaut form drug manufacturing allianceJanuary 17, 2024 | msn.comKBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug ...January 16, 2024 | businesswire.comJohnson & Johnson buys San Diego's Ambrx Biopharma for $2BJanuary 9, 2024 | msn.comWhat Is a Vertically Integrated Business Model?January 4, 2024 | smallbusiness.chron.comIntegrated Circuit Engineering CorporationDecember 2, 2023 | hackaday.comIntegrated BioPharma reports resultsNovember 10, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPLB, INBP, CTXR, and ADXN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.11 -0.90 (-9.99%) As of 10:22 AM EasternAddex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Citius Pharmaceuticals NASDAQ:CTXR$0.92 -0.09 (-8.91%) As of 04:00 PM EasternCitius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Green Planet Bioengineering OTCMKTS:GPLB$0.11 0.00 (0.00%) As of 06/11/2025Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.Integrated BioPharma OTCMKTS:INBP$0.29 -0.02 (-7.03%) As of 02:16 PM EasternIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
